The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.

The US FDA has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for CMT2S.

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off mark ...

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.

Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, reflecting a changing of the guard in celebrity endorsements. The 23-time Grand Slam ...

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK ...

Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.